MannKind Corporation (MNKD)
Price:
5.44 USD
( - -0.21 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Vertex Pharmaceuticals Incorporated
VALUE SCORE:
8
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
NEWS
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
globenewswire.com
2025-10-07 09:02:00DANBURY, Conn. and BURLINGTON, Mass.
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
globenewswire.com
2025-10-07 09:00:00DANBURY, Conn. and BURLINGTON, Mass.
MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
globenewswire.com
2025-09-29 06:05:00WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced the appointment of Ajay Ahuja, MD, MBA, as Chief Medical Officer, effective today.
SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH
businesswire.com
2025-09-16 12:17:00NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of scPharmaceuticals Inc. (NasdaqGS: SCPH) to MannKind Corporation (NasdaqGM: MNKD). Under the terms of the proposed transaction, shareholders of scPharmaceuticals would receive a cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving sp.
MannKind Corporation (MNKD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
seekingalpha.com
2025-09-10 19:30:36MannKind Corporation (NASDAQ:MNKD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 2:35 PM EDT Company Participants Michael Castagna - CEO & Director Conference Call Participants Ross Cohen - Morgan Stanley Presentation Ross Cohen Great. Thank you all for joining us today, and welcome to the Morgan Stanley Healthcare Conference.
MannKind Corporation (MNKD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
seekingalpha.com
2025-09-07 21:55:43MannKind Corporation (NASDAQ:MNKD ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 4:30 PM EDT Company Participants Michael Castagna - CEO & Director Conference Call Participants Tiago Fauth - Wells Fargo Securities, LLC, Research Division Thomas Smith - Leerink Partners LLC, Research Division Presentation Tiago Fauth Equity Analyst All right. Perfect. Thanks, everyone, for joining us.
MannKind Corporation (MNKD) Presents At Cantor Global Healthcare Conference 2025 Transcript
seekingalpha.com
2025-09-07 21:28:57MannKind Corporation (NASDAQ:MNKD ) Cantor Global Healthcare Conference 2025 September 4, 2025 9:45 AM EDT Company Participants Michael Castagna - CEO & Director Conference Call Participants Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Olivia Brayer Research Analyst All right. Good morning, everyone.
MannKind to Present at Upcoming Investor Conferences
globenewswire.com
2025-08-27 16:05:00DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at the upcoming investor conferences. MannKind's Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences:
New Strong Sell Stocks for August 27th
zacks.com
2025-08-27 05:51:08CVGI, INBK and MNKD have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2025.
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal
benzinga.com
2025-08-25 13:57:32MannKind Corporation MNKD on Monday agreed to acquire scPharmaceuticals Inc. SCPH for a deal value of up to approximately $360 million, or $5.35 per share.
MannKind Corporation (MNKD) Mergers and Acquisition Call Transcript
seekingalpha.com
2025-08-25 13:36:03MannKind Corporation (NASDAQ:MNKD ) Mergers and Acquisition Conference Call August 25, 2025 8:30 AM ET Company Participants Christopher B. Prentiss - Chief Financial Officer Michael E.
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
globenewswire.com
2025-08-25 07:31:00DANBURY, Conn. and BURLINGTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and scPharmaceuticals Inc. (Nasdaq: SCPH) today announced the signing of a definitive merger agreement for MannKind to acquire scPharmaceuticals.
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
globenewswire.com
2025-08-25 07:30:00Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX ® , an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet need Upfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents a 36% premium to scPharmaceuticals' 90 trading day VWAP, and total consideration of up to $6.35 per share represents up to a 31% premium to scPharmaceuticals' closing price on August 22, 2025 Strengthens organization by integrating scPharmaceuticals' established commercial and medical capabilities into MannKind's existing infrastructure FUROSCIX ReadyFlow Autoinjector on track for Q3 2025 sNDA submission, potentially unlocking additional market opportunity MannKind to host conference call today at 8:30 a.m. (ET) DANBURY, Conn.
MannKind Corporation (MNKD) Q2 2025 Earnings Conference Call Transcript
seekingalpha.com
2025-08-06 17:20:59MannKind Corporation (NASDAQ:MNKD ) Q2 2025 Earnings Call August 6, 2025 9:00 AM ET Company Participants Christopher B. Prentiss - Chief Financial Officer Michael E.
No data to display
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
globenewswire.com
2025-10-07 09:02:00DANBURY, Conn. and BURLINGTON, Mass.
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
globenewswire.com
2025-10-07 09:00:00DANBURY, Conn. and BURLINGTON, Mass.
MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
globenewswire.com
2025-09-29 06:05:00WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced the appointment of Ajay Ahuja, MD, MBA, as Chief Medical Officer, effective today.
SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH
businesswire.com
2025-09-16 12:17:00NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of scPharmaceuticals Inc. (NasdaqGS: SCPH) to MannKind Corporation (NasdaqGM: MNKD). Under the terms of the proposed transaction, shareholders of scPharmaceuticals would receive a cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving sp.
MannKind Corporation (MNKD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
seekingalpha.com
2025-09-10 19:30:36MannKind Corporation (NASDAQ:MNKD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 2:35 PM EDT Company Participants Michael Castagna - CEO & Director Conference Call Participants Ross Cohen - Morgan Stanley Presentation Ross Cohen Great. Thank you all for joining us today, and welcome to the Morgan Stanley Healthcare Conference.
MannKind Corporation (MNKD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
seekingalpha.com
2025-09-07 21:55:43MannKind Corporation (NASDAQ:MNKD ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 4:30 PM EDT Company Participants Michael Castagna - CEO & Director Conference Call Participants Tiago Fauth - Wells Fargo Securities, LLC, Research Division Thomas Smith - Leerink Partners LLC, Research Division Presentation Tiago Fauth Equity Analyst All right. Perfect. Thanks, everyone, for joining us.
MannKind Corporation (MNKD) Presents At Cantor Global Healthcare Conference 2025 Transcript
seekingalpha.com
2025-09-07 21:28:57MannKind Corporation (NASDAQ:MNKD ) Cantor Global Healthcare Conference 2025 September 4, 2025 9:45 AM EDT Company Participants Michael Castagna - CEO & Director Conference Call Participants Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Olivia Brayer Research Analyst All right. Good morning, everyone.
MannKind to Present at Upcoming Investor Conferences
globenewswire.com
2025-08-27 16:05:00DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at the upcoming investor conferences. MannKind's Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences:
New Strong Sell Stocks for August 27th
zacks.com
2025-08-27 05:51:08CVGI, INBK and MNKD have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2025.
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal
benzinga.com
2025-08-25 13:57:32MannKind Corporation MNKD on Monday agreed to acquire scPharmaceuticals Inc. SCPH for a deal value of up to approximately $360 million, or $5.35 per share.
MannKind Corporation (MNKD) Mergers and Acquisition Call Transcript
seekingalpha.com
2025-08-25 13:36:03MannKind Corporation (NASDAQ:MNKD ) Mergers and Acquisition Conference Call August 25, 2025 8:30 AM ET Company Participants Christopher B. Prentiss - Chief Financial Officer Michael E.
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
globenewswire.com
2025-08-25 07:31:00DANBURY, Conn. and BURLINGTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and scPharmaceuticals Inc. (Nasdaq: SCPH) today announced the signing of a definitive merger agreement for MannKind to acquire scPharmaceuticals.
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
globenewswire.com
2025-08-25 07:30:00Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX ® , an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet need Upfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents a 36% premium to scPharmaceuticals' 90 trading day VWAP, and total consideration of up to $6.35 per share represents up to a 31% premium to scPharmaceuticals' closing price on August 22, 2025 Strengthens organization by integrating scPharmaceuticals' established commercial and medical capabilities into MannKind's existing infrastructure FUROSCIX ReadyFlow Autoinjector on track for Q3 2025 sNDA submission, potentially unlocking additional market opportunity MannKind to host conference call today at 8:30 a.m. (ET) DANBURY, Conn.
MannKind Corporation (MNKD) Q2 2025 Earnings Conference Call Transcript
seekingalpha.com
2025-08-06 17:20:59MannKind Corporation (NASDAQ:MNKD ) Q2 2025 Earnings Call August 6, 2025 9:00 AM ET Company Participants Christopher B. Prentiss - Chief Financial Officer Michael E.